CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
24 hedge funds and large institutions have $2.65M invested in CASI Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
4% more funds holding
Funds holding: 23 → 24 (+1)
2.22% less ownership
Funds ownership: 20.48% → 18.26% (-2.2%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
55% less capital invested
Capital invested by funds: $5.93M → $2.65M (-$3.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$22K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$21.3K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.34K |
| 5 |
Renaissance Technologies
New York
|
+$550 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$994K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.1K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$6.05K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.91K |
| 5 |
Morgan Stanley
New York
|
-$2.06K |
CASI Hedge Fund Activity: Q2 2025 in Review
24 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2025, worth a combined $2.65M — down 55% from $5.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CASI positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $66.4K. The largest seller was Foresite Capital Management VI, cutting an estimated $994K.
- 24 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2025, up from 23 in Q1 2025.
- Funds reported $2.65M of CASI Pharmaceuticals stock for Q2 2025, down 55% quarter-over-quarter.
- 3 funds opened new CASI Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +1 holder.
- The largest CASI Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $66.4K added.
- The largest CASI Pharmaceuticals seller in Q2 2025 was Foresite Capital Management VI, an estimated $994K sold.
Based on aggregated 13F filings for Q2 2025.